May 26, 2021 / 04:28PM GMT
James R. Sapirstein - AzurRx BioPharma, Inc. - President, CEO & Chairman of the Board
Hi, everyone. This is James Sapirstein from AzurRx. Thank you for attending this presentation. And I'll introduce myself in one of our slides. This is a normal company disclaimer that you've seen before.
And what is AzurRx? AzurRx is a clinical stage biotech company. We have 3 indications with 2 assets. If -- for those of you who have invested before, you'll recognize MS1819, which is for exocrine pancreatic insufficiency. I'll talk about the studies on the subsequent slides. And we have niclosamide, which is -- micronized version of niclosamide, 2 indications. One is for COVID-19 infections. We launched that trial. We're waiting for our first patient any day now, and we are about to launch another trial for immune checkpoint inhibitor-associated colitis Again, I'll explain that in a few minutes. Why did I license this? And quite frankly, it's really in line with oral gastroenterology, gut-targeted therapies, and we're looking to address unmet clinical needs in multimillion-dollar markets.
Our team.
AzurRx BioPharma Inc at SRAX Sequire Rocky Mountain Microcap Conference (Virtual) Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers